clinical trial · NCT06019507
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
Liver TransplantationTCD601CyclophosphamideTACMMFCorticosteroids
brief summary
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
started
Jun 29, 2022
primary completion
Jun 1, 2026
completion
Jun 1, 2029
last updated
Nov 27, 2024
official title
A 60 Month, Single-arm, Proof-of-concept Study to Induce Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients Using Siplizumab, an Anti-CD2 Antibody in Combination With Cyclophosphamide and Splenectomy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol